Br[C:2]1[CH:7]=[CH:6][N:5]=[C:4]([C:8]([NH:10][C:11]2[CH:16]=[CH:15][CH:14]=[C:13]([C:17]3[N:21]([CH:22]4[CH2:24][CH2:23]4)[CH:20]=[N:19][CH:18]=3)[CH:12]=2)=[O:9])[CH:3]=1.B(O)O.C(=O)([O-])[O-].[K+].[K+]>C1(C)C=CC=CC=1>[CH:22]1([N:21]2[C:17]([C:13]3[CH:12]=[C:11]([NH:10][C:8]([C:4]4[CH:3]=[C:2]([C:3]5[CH:4]=[N:5][CH:6]=[CH:7][CH:2]=5)[CH:7]=[CH:6][N:5]=4)=[O:9])[CH:16]=[CH:15][CH:14]=3)=[CH:18][N:19]=[CH:20]2)[CH2:24][CH2:23]1A suspension of 4-bromo-N-(3-(1-cyclopropyl-1H-imidazol-5-yl)phenyl)picolinamide (75.0 mg, 0.196 mmol), boronic acid (33.8 mg, 0.274 mmol), dppf(Pd)Cl2 (14.3 mg, 0.0196), potassium carbonate (81.3 mg, 0.588 mmol) in degassed toluene (1 mL), degassed water (0.5 mL) and degassed isopropanol (0.5 mL) was heated at 95° C. for 2 hours. The aqueous phase was discarded and the solvent removed under reduced pressure from the organic portion. Purification by reverse phase HPLC provided N-(3-(1-cyclopropyl-1H-imidazol-5-yl)phenyl)-3,4′-bipyridine-2′-carboxamide (17.3 mg, 23%) as a white solid.